TY - JOUR
T1 - Synthesis, resolution, and biological evaluation of atropisomeric (aR)- and (aS)-16-methyllamellarins N
T2 - Unique effects of the axial chirality on the selectivity of protein kinases inhibition
AU - Yoshida, Kenyu
AU - Itoyama, Ryosuke
AU - Yamahira, Masashi
AU - Tanaka, Junji
AU - Loaëc, Nadège
AU - Lozach, Olivier
AU - Durieu, Emilie
AU - Fukuda, Tsutomu
AU - Ishibashi, Fumito
AU - Meijer, Laurent
AU - Iwao, Masatomo
PY - 2013/9/26
Y1 - 2013/9/26
N2 - The total synthesis of the optically active (aR)- and (aS)-16- methyllamellarins N (3a and 3b) was achieved via resolution on HPLC chiral stationary phase. The kinase inhibitory activities of both enantiomers were evaluated on eight protein kinases relevant to cancer and neurodegenerative diseases (CDK1/cyclin B, CDK2/cyclin A, CDK5/p25, GSK-3α/β, PIM1, DYRK1A, CLK3, and CK1). Isomer (aR)-3b exhibited potent but nonselective inhibition on all protein kinases except CK1, while (aS)-3a selectively inhibited only GSK-3α/β, PIM1, and DYRK1A. The different inhibition profiles of (aS)-3a and (aR)-3b were elucidated by docking simulation studies. Although parental lamellarin N (2) inhibited the action of topoisomerase I, both (aS)-3a and (aR)-3b showed no inhibition of this enzyme. The phenotypic cytotoxic activities of 2, (aS)-3a, and (aR)-3b on three cancer cell lines (HeLa, SH-SY5Y, and IMR32) changed according to their topoisomerase I and protein kinase inhibitory activities.
AB - The total synthesis of the optically active (aR)- and (aS)-16- methyllamellarins N (3a and 3b) was achieved via resolution on HPLC chiral stationary phase. The kinase inhibitory activities of both enantiomers were evaluated on eight protein kinases relevant to cancer and neurodegenerative diseases (CDK1/cyclin B, CDK2/cyclin A, CDK5/p25, GSK-3α/β, PIM1, DYRK1A, CLK3, and CK1). Isomer (aR)-3b exhibited potent but nonselective inhibition on all protein kinases except CK1, while (aS)-3a selectively inhibited only GSK-3α/β, PIM1, and DYRK1A. The different inhibition profiles of (aS)-3a and (aR)-3b were elucidated by docking simulation studies. Although parental lamellarin N (2) inhibited the action of topoisomerase I, both (aS)-3a and (aR)-3b showed no inhibition of this enzyme. The phenotypic cytotoxic activities of 2, (aS)-3a, and (aR)-3b on three cancer cell lines (HeLa, SH-SY5Y, and IMR32) changed according to their topoisomerase I and protein kinase inhibitory activities.
UR - http://www.scopus.com/inward/record.url?scp=84884990704&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84884990704&partnerID=8YFLogxK
U2 - 10.1021/jm400719y
DO - 10.1021/jm400719y
M3 - Article
C2 - 23981088
AN - SCOPUS:84884990704
SN - 0022-2623
VL - 56
SP - 7289
EP - 7301
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 18
ER -